Back to top
more

ArQule, Inc. (ARQL)

(Delayed Data from NSDQ)

$6.51 USD

6.51
879,521

+0.23 (3.66%)

Updated May 3, 2019 04:00 PM ET

After-Market: $6.50 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neena Mishra headshot

Why Biotech ETFs are Surging to New Highs

by Neena Mishra

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

Sweta Killa headshot

Biotech ETFs Hit New Highs on Deal Activities

by Sweta Killa

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Company News for Dec 10, 2019

by Zacks Equity Research

Companies in the news are: ARQL, THOR, CGC, FATE

Kinjel Shah headshot

Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms

by Kinjel Shah

Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.

Week Begins with Biotech Mergers

by Zacks Equity Research

Week Begins with Biotech Mergers

Mark Vickery headshot

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

by Mark Vickery

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

ArQule (ARQL) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ArQule (ARQL) delivered earnings and revenue surprises of 0.00% and -82.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About ArQule (ARQL) Rating Upgrade to Buy

by Zacks Equity Research

ArQule (ARQL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ArQule (ARQL) in Focus: Stock Moves 6.2% Higher

by Zacks Equity Research

ArQule (ARQL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ArQule (ARQL) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

ArQule (ARQL) delivered earnings and revenue surprises of 11.11% and -80.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.

Analysts Estimate ArQule (ARQL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ArQule (ARQL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Makes ArQule (ARQL) a New Buy Stock

by Zacks Equity Research

ArQule (ARQL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Do Options Traders Know Something About ArQule (ARQL) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.

ArQule (ARQL) Catches Eye: Stock Jumps 8.1%

by Zacks Equity Research

ArQule (ARQL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Company News For Jun 17, 2019

by Zacks Equity Research

Companies In The News Are: FB,BXG,ARQL,KURA

ArQule (ARQL) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ArQule (ARQL) delivered earnings and revenue surprises of -12.50% and -20.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate ArQule (ARQL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ArQule (ARQL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About ArQule (ARQL) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in ArQule (ARQL) Stock

by Zacks Equity Research

ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.

Options Traders Expect Huge Moves in ArQule (ARQL) Stock

by Zacks Equity Research

ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.

ArQule (ARQL) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ArQule (ARQL) delivered earnings and revenue surprises of 16.67% and 104.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for ArQule (ARQL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.

    Medical-Drugs Stock Outlook: No Respite from Near-Term Pain

    by Zacks Equity Research

    Small drugmakers, in general, are having a rather poor year, the principle reason being failure of key pipeline candidates in pivotal studies.

      ArQule (ARQL) Beats Q2 Earnings and Revenue Estimates

      by Zacks Equity Research

      ArQule (ARQL) delivered earnings and revenue surprises of 150.00% and 78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?